Pathophysiology, clinical presentation, and treatment of psoriasis: a review
Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis …
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …
population. This guideline addresses important clinical questions that arise in psoriasis …
Psoriasis
Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide,
presenting at any age, and leading to a substantial burden for individuals and society. It is …
presenting at any age, and leading to a substantial burden for individuals and society. It is …
IL-17 and Th17 Cells
T Korn, E Bettelli, M Oukka… - Annual review of …, 2009 - annualreviews.org
CD4+ T cells, upon activation and expansion, develop into different T helper cell subsets
with different cytokine profiles and distinct effector functions. Until recently, T cells were …
with different cytokine profiles and distinct effector functions. Until recently, T cells were …
TH17 cell heterogeneity and its role in tissue inflammation
Since their discovery almost two decades ago, interleukin-17-producing CD4+ T cells (TH17
cells) have been implicated in the pathogenesis of multiple autoimmune and inflammatory …
cells) have been implicated in the pathogenesis of multiple autoimmune and inflammatory …
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled …
KB Gordon, B Strober, M Lebwohl, M Augustin… - The Lancet, 2018 - thelancet.com
Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation …
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation …
[HTML][HTML] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with …
Background Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating
moderate to severe psoriasis in a phase II trial. Objectives We sought to compare efficacy …
moderate to severe psoriasis in a phase II trial. Objectives We sought to compare efficacy …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
E Sbidian, A Chaimani, R Guelimi… - Cochrane Database …, 2023 - cochranelibrary.com
Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …
manifestations, or both, and it has a major impact on quality of life. Although there is …
Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
Background Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of
treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to …
treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to …
Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies
F Alinaghi, M Calov, LE Kristensen… - Journal of the American …, 2019 - Elsevier
Background Wide-ranging prevalence estimates of psoriatic arthritis (PsA) in patients with
psoriasis have been reported. Objectives To assess the prevalence and incidence of PsA in …
psoriasis have been reported. Objectives To assess the prevalence and incidence of PsA in …